Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Public ClinicalTrials.gov record NCT05732831. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05732831
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Tango Therapeutics, Inc.
- Industry
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- TNG462 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2023
- Primary completion
- Apr 30, 2026
- Completion
- Aug 31, 2026
- Last update posted
- Apr 20, 2026
2023 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94304 | Recruiting |
| Grand Valley Oncology | Grand Junction | Colorado | 81505 | Recruiting |
| Florida Cancer Specialists & Research Institute | Lake Mary | Florida | 32746 | Completed |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | Recruiting |
| University Chicago Medicine | Chicago | Illinois | 60637 | Recruiting |
| Carle Cancer Center | Urbana | Illinois | 61801 | Recruiting |
| Midwestern Regional Medical Center, City of Hope Chicago | Zion | Illinois | 60099 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02214 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Henry Ford Cancer Center | Detroit | Michigan | 48202 | Recruiting |
| New York University Langone Health | New York | New York | 10016 | Recruiting |
| Sarah Cannon Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | Recruiting |
| Next Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05732831, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05732831 live on ClinicalTrials.gov.